Evolus, Inc. (EOLS)

Market Cap	433.32M -41.1%
Revenue (ttm)	301.79M +9.6%
Net Income	-43.42M
EPS	-0.67
Shares Out	65.85M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	490,450
Open	6.70
Previous Close	6.72
Day's Range	6.52 - 6.75
52-Week Range	3.86 - 10.62
Beta	1.29
Analysts	Strong Buy
Price Target	15.50 (+135.56%)
Earnings Date	May 4, 2026

About EOLS

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newpo...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 8, 2018
• Employees: 350
• Stock Exchange: NASDAQ
• Ticker Symbol: EOLS
• Website: https://www.evolus.com

Financial Performance

In 2025, Evolus's revenue was $297.18 million, an increase of 11.61% compared to the previous year's $266.27 million. Losses were -$51.64 million, 2.42% more than in 2024.

Analyst Summary

According to 5 analysts, the average rating for EOLS stock is "Strong Buy." The 12-month stock price target is $15.5, which is an increase of 135.56% from the latest price.

Price Target

$15.5

(135.56% upside)

Analyst Consensus: Strong Buy